SCHEMBL3528366

SCHEMBL3528366

O=C(Nc1ncc2c(n1)CCC(NS(=O)(=O)c1ccccc1)C2)c1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.51
CYP3A4 P08684 3/20 0.51
HTT P42858 1/20 0.51
HDAC8 Q9BY41 6/20 0.46
HDAC6 Q9UBN7 2/20 0.46
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TBXA2R P21731 4/20 0.43
PTGDR2 Q9Y5Y4 4/20 0.43
PTGDR Q13258 3/20 0.43
APOB P04114 1/20 0.42
MTTP P55157 1/20 0.42
CYP2C19 P33261 2/20 0.42
GAA P10253 1/20 0.42
CYP2C9 P11712 2/20 0.42
ABCB11 O95342 1/20 0.42
DRD1 P21728 1/20 0.42
CCKAR P32238 1/20 0.42
HTR1A P08908 1/20 0.41
HTR1D P28221 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530287 0.95 CYP1A2 (0.48) CYP1A2CYP3A4HTTHDAC8HDAC6
SCHEMBL3536455 0.90 HDAC8 (0.54) CYP1A2CYP3A4HTTHDAC8HDAC6
SCHEMBL3533155 0.89 KMT2A (0.48) CYP1A2CYP3A4HTTHDAC8HDAC6
SCHEMBL3529909 0.88 CYP1A2 (0.48) CYP1A2CYP3A4HTTHDAC8HDAC6
SCHEMBL3536154 0.84 HDAC8 (0.45) CYP1A2CYP3A4HTTHDAC8HDAC6
SCHEMBL3526812 0.84 CYP1A2 (0.43) CYP1A2CYP3A4HTTHDAC8HDAC6
SCHEMBL3536495 0.83 APP (0.44) CYP1A2CYP3A4HTTHDAC8KDM4E
SCHEMBL3534559 0.83 CYP1A2 (0.46) CYP1A2CYP3A4HTTHDAC8KDM4E
SCHEMBL3534412 0.82 CYP1A2 (0.42) CYP1A2CYP3A4HTTHDAC8HDAC6
SCHEMBL3528132 0.81 HDAC8 (0.52) CYP1A2CYP3A4HTTHDAC8KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1742925-B1 SUBSTITUTED 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL COMPOUNDS AND 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL COMPOUNDS GRUENENTHAL GMBH (DE) 2014-04-23 EP claimed
US-20070249631-A1 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds GRUENENTHAL GMBH (DE) 2007-10-25 US claimed
EP-1742925-B1 SUBSTITUTED 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL COMPOUNDS AND 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL COMPOUNDS GRUENENTHAL GMBH (DE) 2014-04-23 EP disclosed
US-7662828-B2 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds GRUENENTHAL GMBH (DE) 2010-02-16 US disclosed
US-20090176811-A1 Substituted 5,6,7,8-Tetrahydro-pyrido[4,3-d]pyrimidine-2-yl Compounds and 5,6,7,8-Tetrahydro-quinazoline-2-yl Compounds GRUENENTHAL GMBH (DE) 2009-07-09 US disclosed
US-20070249631-A1 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds GRUENENTHAL GMBH (DE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249631-A1 Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds P2RX7, CYP2C8, P2RX5 CYP1A2 51/4885CYP3A4 43/4885HTT 858/4885
US-20090176811-A1 Substituted 5,6,7,8-Tetrahydro-pyrido[4,3-d]pyrimidine-2-yl Compounds and 5,6,7,8-Tetrahydro-quinazoline-2-yl Compounds P2RX7, P2RX5, DPYD CYP1A2 47/4885CYP3A4 52/4885HTT 1459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.